Analysis: human immunity to Cas9 bigger #CRISPR therapeutic hurdle than off-targets?

Cas9-immunity-pre-print

Some in CRISPR-Cas9-land who are focused on potential future clinical applications are kind of rejoicing or at least sighing a breath of relief. This upbeat swing in the atmosphere (from investors especially) was sparked by retraction of that paper, the one initially reporting tons of supposed off-target CRISPR-Cas9 activity in mice, which turned out to be a “nothing …

Analysis: human immunity to Cas9 bigger #CRISPR therapeutic hurdle than off-targets? Read More »